Fortress Biotech, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

FBIO$1.99+7.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets


· · December 31, · · December 31,
· · 2024 · · 2023
ASSETS · ·
Current assets · ·
Cash and cash equivalents	$57,263	$80,927
Accounts receivable, net	10,231	15,222
Inventory	14,431	10,206
Other receivables - related party	171	167
Prepaid expenses and other current assets	7,110	10,500
Assets held for sale	1,165	—
Total current assets	90,371	117,022

Property, plant and equipment, net	3,260	6,505
Operating lease right-of-use asset, net	13,861	16,990
Restricted cash	1,552	2,438
Intangible assets, net	31,863	20,287
Other assets	3,316	4,284
Total assets	$144,223	$167,526

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued expenses	$65,501	$73,562
Income taxes payable	932	843
Common stock warrant liabilities	214	886
Operating lease liabilities, short-term	2,623	2,523
Partner company convertible preferred shares, short-term, net	—	3,931
Partner company installment payments - licenses, short-term	625	3,000
Other current liabilities	1,504	163
Total current liabilities	71,399	84,908

Notes payable, long-term, net	57,962	60,856
Operating lease liabilities, long-term	14,750	18,282
Other long-term liabilities	1,756	1,893
Total liabilities	145,867	165,939

Commitments and contingencies (Note 14)

Stockholders’ equity (deficit)
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively, liquidation value of $25.00 per share	3	3
Common stock, $0.001 par value, 200,000,000 shares authorized, 27,908,839 and 15,093,053 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	28	15
Additional paid-in-capital	763,573	717,396
Accumulated deficit	(740,867)	(694,870)
Total stockholders' equity attributed to the Company	22,737	22,544

Non-controlling interests	(24,381)	(20,957)
Total stockholders' equity (deficit)	(1,644)	1,587
Total liabilities and stockholders' equity (deficit)	$144,223	$167,526

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.